Hansa Biopharma AB (publ) (STO:HNSA)

Market Cap	1.55B
Revenue (ttm)	171.32M
Net Income (ttm)	-807.24M
Shares Out	67.81M
EPS (ttm)	-12.85
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	52,184
Average Volume	200,751
Open	22.92
Previous Close	22.82
Day's Range	22.12 - 23.10
52-Week Range	21.64 - 57.30
Beta	1.55
RSI	41.21
Earnings Date	Mar 21, 2025

About Hansa Biopharma AB

Hansa Biopharma AB (publ), a biopharmaceutical company, engages in development and commercialization of treatments for patients with rare immunological conditions in Europe and the United States. The company offers Idefirix(imlifidase), which targets and cleaves all classes of immunoglobulin G (IgG) antibodies for the desensitization treatment of sensitized adult kidney transplant patients with a positive crossmatch test. It is also developing Novel immunoglobulin cleaving enzymes for Repeat dosing (NiceR) for the treatment of autoimmune diseas...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2007
• Employees: 135
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: HNSA

Financial Performance

In 2024, Hansa Biopharma AB's revenue was 171.32 million, an increase of 27.76% compared to the previous year's 134.09 million. Losses were -807.24 million, -2.94% less than in 2023.